Loading...
Market
Story
Illumina to Spin Off Grail in June, Retains 14.5 Percent Stake
Jun 3, 2024, 11:05 PM
Illumina Inc. has officially announced the spin-off of its cancer test subsidiary, Grail. The board of directors approved the spin-off, marking the end of a nearly four-year-long saga. As part of the divestment, Illumina will issue Grail shares to its investors while retaining a 14.5 percent stake in the company. Additionally, the board declared a spin-off dividend of Grail shares. The spin-off is set to be completed in June.
View original story
Similar markets
Below $5.33 billion • 33%
$5.33 billion to $5.38 billion • 34%
Above $5.38 billion • 33%
Below $15 billion • 25%
$15 billion - $17 billion • 25%
$17 billion - $19 billion • 25%
Above $19 billion • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Below $21.40 billion • 33%
$21.40 billion to $21.50 billion • 34%
Above $21.50 billion • 33%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Below $100M • 25%
$100M - $150M • 25%
$151M - $200M • 25%
Above $200M • 25%
Below $3.3B • 25%
$3.3B to $3.4B • 25%
$3.4B to $3.5B • 25%
Above $3.5B • 25%